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Abstract 
Background: An increasing number of cancer patients are receiving ambulatory chemotherapy to improve their 
quality of life and reduce medical expenses. During outpatient chemotherapy, adverse events (AEs) occurring at 
home must be carefully monitored. We investigated the use of our institution’s telephone consultation service that is 
available to patients and their caregivers for advice on and the management of AEs and complications arising from 
cancer treatment.
Patients and methods: Telephone consultants assessed and graded AEs according to the Common Terminology 
Criteria for Adverse Events (CTCAE). All patient characteristics, AEs, and background factors were analyzed using logis‑
tic regression analyses.
Results: Between August 2011 and August 2012, we included 253 patients and 344 telephone consultations regard‑
ing AEs during chemotherapy for analysis in this study. Grade 1 AEs were assessed in 223 consultations (65%); grade 
2 AEs, in 90 consultations (26%); and grade 3 AEs, in 31 consultations (9%). A multivariate logistic regression analysis 
revealed an association between a change in patient schedules and the occurrence of grade 2 or worse AEs (Hazard 
ratio = 6.58, P < 0.001). Changes in planned chemotherapy occurred more often in cases involving male patients 
(Hazard ratio = 2.70, P = 0.02) and in cases of grade 2 or worse AEs (Hazard ratio = 6.58, P < 0.001).
Conclusion: We found that AE assessment using CTCAE via a telephone consultation service is useful for both the 
triage of patients and the prediction of severe AEs that may change clinical schedules.
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Background
In the oncology setting, there has been an increase in the 
use of ambulatory treatments, which represent a com-
pletely different context to hospitalization. Compared with 
the inpatient setting, ambulatory chemotherapy results in 
a better quality of life (QOL) and lower treatment costs for 
patients. However, administering ambulatory chemother-
apy is challenging because of the high volume of patients, 
time pressures, and the lower level of control. Moreover, 
patients may need to self-administer essential medica-
tions, and side effects often occur at home.
Cancer patients receiving chemotherapy may suf-
fer from treatment-related adverse events (AEs) such as 
hair loss, nausea, fatigue, and potentially life-threatening 
effects such as lowered blood counts. Chemotherapy for 
cancer patients often corresponds with a period of poor 
QOL because of these AEs; however, most AEs can be 
managed. Before the initiation of chemotherapy, physi-
cians and nurses talk with patients about potential AEs 
and the importance of monitoring any changes they 
notice during treatment to assess toxicity.
Monitoring AEs, including side effects observed 
during chemotherapy, is a standard part of clinical 
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trials, but should also be a routine consideration in 
everyday practice because AEs directly influence the 
QOL of the patient. The Common Terminology Cri-
teria for Adverse Events (CTCAE) is a standard clas-
sification system that has been used for reporting AEs 
in cancer clinical trials [1]. Toxicity data are routinely 
collected by medical staff; however, both the interpre-
tation and registration of symptoms are susceptible to 
mistakes, omissions, and misunderstandings due to 
various factors. The CTCAE includes items derived 
from measured objective factors, analytical tests, and 
the patients’ subjective symptoms [2], all of which are 
currently reported by clinicians. Clinical staff obtain, 
interpret, and report patient symptoms, a process that 
can be cumbersome and susceptible to data degrada-
tion. In practice, symptoms are abstracted by research 
support staff members through review of patients’ 
written medical records.
The telephone has been accepted as a useful means of 
communication for the management of patient care since 
the 1960s. Previous research has validated the safety and 
effectiveness of telephone helplines in many specialist 
services including depression, pain management, and 
cancer care [3, 4]. Moreover, telephone services have 
been shown to be extremely useful to patients because 
they allow for rapid access to oncology facilities in the 
event of chemotherapy toxicities [5].
In our hospital, a telephone consultation service for 
patients receiving ambulatory chemotherapy is man-
aged by the comprehensive care team of the outpa-
tient treatment unit. The purpose of this service is 
to provide rapid support and assessment of AEs for 
patients. The use of a telephone service to assess AEs 
may affect the accuracy of toxicity assessment dur-
ing ambulatory chemotherapy. Hence, we conducted 
this study to clarify the potential for predicting severe 
AEs of ambulatory chemotherapy by patient assess-
ment via a passive telephone consultation service and 
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Fig. 1 Outline of the telephone consultation service and endpoints of the study.
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Patients and methods
Survey cohort
The study was conducted in the outpatient treatment 
unit of the National Cancer Center Hospital, Tokyo. 
The cases of consultation via the telephone consulta-
tion service between August 2011 and August 2012 were 
enrolled in the study. Any consultation cases regarding 
issues other than AEs (for example, consultations about 
the method of dosing or confirmation of the next visit-
ing date) were excluded from the analyses. The study is 
conducted in accordance with the ‘Helsinki Declaration’, 
and approved by the institutional review boards of the 
National Cancer Center Hospital Tokyo (ID: 2012-151). 
Patients consented to the retrospective use of their medi-
cal records for research purposes based on comprehen-
sive permitting system of the National Cancer Center 
Hospital Tokyo.
Telephone consultation service
The telephone consultation service initiated by patients 
who receiving chemotherapy at the outpatient treatment 
unit of the hospital was operated by a rotation of staff 
members consisting of nurses, pharmacists, and medi-
cal oncologists of the outpatient treatment unit. Patients 
receiving chemotherapy in the outpatient setting used 
the telephone service to talk to a medical professional 
about all aspects of their chemotherapy, including 
dealing with side effects, route of administration and 
their mental health. As part of this service, consultants 
assessed and graded AEs according to the CTCAE, ver-
sion 4.0. Consultants referenced common records in the 
electronic health record system to share patients’ clini-
cal information using the telephone consultation service 
(Fig. 1).
Statistical analysis
We set the clinical endpoint of the study as any event that 
occurred after each telephone consultation in surveil-
lance period. These included changes in clinical schedule 
before the next scheduled visit (additional consultation 
call, unscheduled visit, and urgent hospitalization) and 
any changes in therapy (dosage reduction, deferred treat-
ment, and discontinuation of treatment). We conducted 
statistical analyses using IBM SPSS version 18.0 (SPSS, 
Chicago, IL). All patient characteristics and background 
factors were analyzed using logistic regression analyses. 
Multivariate logistic regression analyses after univariate 
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Fig. 2 Diagrammatic representation of the study.
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association with clinical events. P values less than 0.05 in 
a 2-sided test were considered significant.
Results
Characteristics of the study cohort
In the outpatient treatment center, a total of 25,000 
patients were received chemotherapy as outpatients 
from August 2011 through August 2012. Two-hundred 
fifty three cancer patients used the telephone con-
sultation service in this same time period. Of the 509 
telephone consultations for these 253 patients, 409 con-
sultations concerned AEs during chemotherapy and 65 
consultations were excluded because they were repeat 
calls in a term of surveillance (Fig. 1), resulting in a total 
of 344 consultations being included in this study (Fig. 2). 
The 344 subject consultations included in the analy-
ses are described in Table  1. The mean age of patients 
was 57.2  years (standard deviation, 12.8  years), and 
80.5% were female. Most telephone calls were received 
directly from patients (91.6%), with the remainder of 
calls made by a caregiver (8.4%). Grade 1 AEs were 
assessed in 223 consultations (65%), grade 2 AEs in 90 
consultations (26%), and grade 3 AEs in 31 consulta-
tions (9%). Of the grade 3 AEs, 13 consultations regard-
ing suspicions of febrile neutropenia were included. The 
most common AEs consulted for were the occurrence of 
pain (14%), fever (11%), nausea/vomiting (7%), signs of 
febrile neutropenia (7%), and diarrhea (6%) (Additional 
file  1: Figure S1A). Chemotherapy regimens of patients 
included adriamycin  +  cyclophosphamid (22%), car-
boplatin +  paclitaxel (9%), gemcitabine (7%), S-1 (7%), 
cyclophosphamide  +  epirubicine  +  5-FU (7%), pacli-
taxel (7%), and adriamycin (4%) (Additional file 1: Figure 
S1B).
Association of adverse events and clinical events
For assessment of grade 1 AEs, 184 consultations (83%) 
led to no change of clinical schedules but of the other 
39 consultations (17%), 21 led to another call before the 
next appointment to see a doctor, 15 lead to an unsched-
uled visit, and 3 resulted in urgent hospitalization due 
to AEs. A total of 202 consultations (91%) resulted in 
no change in therapy, whereas 21 consultations (9%) did 
result in a change in therapy (13 cases: dosage reduction; 
4 cases: deferred treatment; 4 cases: discontinuation of 
treatment). For assessment of grade 2 AEs, 35 consulta-
tions (39%) did not and 51 consultations (61%) did result 
in a change of clinical schedules (19 cases: additional 
call before next appointment to see a doctor; 25 cases: 
unscheduled visits; 11 cases: urgent hospitalization due 
to AEs). Fifty-three of these consultations (59%) resulted 
in no change in therapy and 37 consultations (41%) did 
result in a change in therapy (21 cases: dosage reduction; 
5 cases: deferred treatment; 11 cases: discontinuation of 
treatment). For assessment of grade 3 AEs, 15 consulta-
tions (48%) led to no change of clinical schedules and 
16 consultations (62%) did result in a change of clinical 
schedules (6 cases: additional call before next appoint-
ment to see a doctor; 2 cases: unscheduled visits; 8 cases: 
urgent hospitalization due to AEs). Nineteen consulta-
tions (61%) resulted in no change in therapy, but 12 con-
sultations (39%) did (4 cases: dosage reduction; 5 cases: 
deferred treatment; 3 cases: discontinuation of treat-
ment) (Table 2).
Table 1 Demographic characteristics of the study cohort
Characteristics Number %
All grades 344 grades 100.0
Age, years (average, standard deviation) (57.2, 12.8)
 ≤39 33 9.6
 40–49 78 22.7
 50–59 67 19.5
 60–69 94 27.3
 70–79 68 19.8
 ≥80 4 1.1
Sex
 Male 67 19.5
 Female 277 80.5
Consulter
 Patients 315 91.6
 Caregiver 29 8.4
Cancer type
 Breast cancer 188 54.7
 Pancreatic cancer 46 13.4
 Ovarian cancer 29 8.4
 Colorectal cancer 27 7.8
 Soft tissue sarcoma 13 3.8
 Gastric cancer 10 2.9
 Biliary tract cancer 8 2.3
 Liver cancer 7 2.0
 Malignant lymphoma 6 1.7
 Primary unknown cancer 5 1.5
 Other malignancies 5 1.5
Objective of therapy
 Adjuvant chemotherapy 197 57.3
 Palliative chemotherapy 141 41.0
 Chemotherapy for blood malignancy 6 1.7
Grading of adverse event
 Grade 1 223 64.8
 Grade 2 90 26.2
 Grade 3 31 9.0
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Factors associated with clinical events
The results of the univariate analysis revealed a consider-
able impact of AE grade on changes in clinical schedule 
(Table 3). The results of the univariate analysis regarding 
associations with changes in planned chemotherapy are 
also shown in Table  3. Using the factors from the uni-
variate analysis that were significantly associated with 
changes in schedule, we then performed a multivariate 
logistic regression analysis. The results indicated that a 
change of schedule during ambulatory chemotherapy 
tended to occur more often with grade ≥2 AEs (Hazard 
ratio = 6.58, P < 0.001). In addition, changes in planned 
chemotherapy tended to occur more often amongst male 
patients (Hazard ratio = 2.70, P = 0.02) and more often 
in cases of grade ≥2 AEs (Hazard ratio = 6.58, P < 0.001). 
Although we conducted additional analyses including all 
variables, these results were materially unchanged.
Discussion
The results of this study indicate that assessment of AEs 
via a telephone consultation service during ambulatory 
chemotherapy is a useful way to assess the medical con-
dition of outpatients receiving chemotherapy. Notably, 
assessment of grade ≥2 AEs was significantly associated 
with changes in clinical schedule (additional call before 
next appointment to see a doctor, unscheduled visits, and 
urgent hospitalization due to AEs) and changes in chem-
otherapy (dosage reduction, deferred treatment, and dis-
continuation of treatment).
Of the symptoms reported by patients in this study, 
pain, fever, and nausea/vomiting were the most com-
mon. This finding is similar to the common problem of 
telephone help line in of previous reports [6].
In the ambulatory oncology setting, use of a telephone 
service can prevent symptoms from becoming unman-
ageable and possibly help patients avoid unnecessary 
and costly visits to the hospital. Moreover, such a tel-
ephone service may be used to monitor AEs, evaluate the 
effectiveness of treatment, and increase overall patient 
satisfaction [7]. However, assessment of AEs using a tel-
ephone consultation service differs from the traditional 
face-to-face assessments by clinicians. Therefore, it is 
important to monitor AEs using standardized symptom 
inventory tools administered to patients in an ambula-
tory care setting during scheduled visits. In this study, we 
used the CTCAE version 4.0 to assess patient AEs during 
ambulatory chemotherapy. The assessment of AEs that 
we found to be significantly associated with the clinical 
endpoints could add to the current approach to symptom 
monitoring in ambulatory cancer treatment.
Table 2 Change in schedules or planned chemotherapy among patients with grade 1–3 adverse events
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The use of telephone triage to monitor adverse effects is 
an essential component of contemporary oncology prac-
tice. In this study, we showed the potential of telephone 
triage using CTCAE (grade ≥2 AEs) and its benefit in 
ambulatory cancer treatment. On the other hand, the tri-
age process is the initial interaction between the patients 
and the telephone consultants, who must therefore be 
experienced oncologists and have good communication 
and assessment skills in order to avoid underestimating 
the significance of reported symptoms [8].
In this study, we showed a greater benefit of telephone 
triage for grade 2 but not grade 3 AEs. Grade 3 AEs were 
generally suspicion of febrile neutropenia (77%). In a 
telephone consultation service, consultants cannot con-
firm this AE by blood tests; therefore, consultants with 
oncology experience are required to adequately assess 
Table 3 Factors associated with clinical events
Characteristics Event 1: change of schedule Event 2: change in therapy
All grades Hazard ratio 95% CI P Hazard ratio 95% CI P
Univariate analyses
 Age
  ≤64 vs. ≥65 1.08 0.66–1.73 0.77 0.66 0.39–1.13 0.13
 Sex
  Male vs. female 1.71 0.99–2.96 >0.05 3.07 1.70–5.52 <0.001
 Consulter
  Patients vs. caregiver 0.47 0.22–1.01 >0.05 0.38 0.17–0.84 <0.05
 Cancer type
  Breast cancer 0.85 0.54–1.33 0.47 0.55 0.32–0.93 0.03
  Pancreatic cancer 1.44 0.76–2.73 0.27 2.14 1.08–4.23 0.03
  Ovarian cancer 0.84 0.36–1.97 0.69 0.63 0.21–1.88 0.41
  Colorectal cancer 0.56 0.22–1.41 0.22 0.84 0.31–2.29 0.73
  Soft tissue sarcoma 1.87 0.61–5.70 0.27 1.18 0.32–4.42 0.80
  Gastric cancer 0.91 0.23–3.59 0.89 2.71 0.74–9.87 0.13
  Biliary tract cancer 1.28 0.30–5.47 0.74 1.31 0.26–6.65 0.74
  Liver cancer 0.85 0.16–4.44 0.85 3.02 0.66–13.83 0.15
  Malignant lymphoma 4.34 0.79–24.27 0.09 0.78 0.09–6.78 0.82
  Primary unknown cancer 0.53 0.06–4.78 0.57 0.98 0.11–8.89 0.98
  Endometrial cancer 1.43 0.24–8.67 0.70 2.66 0.44–16.22 0.29
 Objective of therapy
  Adjuvant chemotherapy 0.70 0.51–0.95 <0.05 0.45 0.31–0.65 <0.001
  Palliative chemotherapy 1.05 0.84–1.33 0.65 1.57 1.20–2.05 0.001
  Chemotherapy for blood malignancy 0.23 0.04–1.27 0.09 1.28 0.14–11.16 0.82
Grading of adverse event
  Grade 2 + grade 3 vs. grade 1 6.70 4.06–11.05 <0.001 6.55 3.67–11.67 <0.001
  Grade 3 vs. grade 1 + grade 2 0.38 0.18–0.78 <0.01 0.33 0.15–0.70 <0.01
Multivariate analyses
 Sex
  Male vs. female 2.70 1.15–6.30 0.02
 Consulter
  Patients vs. caregiver 1.65 0.67–4.06 0.28
 Cancer type
  Breast cancer 0.80 0.36–1.77 0.58
  Pancreatic cancer 0.58 0.21–1.31 0.17
 Objective of therapy
  Adjuvant chemotherapy 0.96 0.69–1.33 0.78 0.77 0.52–1.15 0.20
 Grading of adverse event
  Grade 2 + grade 3 vs. grade 1 6.58 3.93–11.02 <0.001 6.25 3.31–11.80 <0.001
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any suspicions of febrile neutropenia, as guidelines sug-
gest prompt empirical oral antibiotic therapy for low-
risk febrile neutropenia patients [9]. In our telephone 
consultation service, consultants prompted patients to 
take oral antibiotics if they reported suspicions of febrile 
neutropenia based on this guideline. This in turn might 
reduce the risk of unscheduled medical intervention and 
changes in planned chemotherapy. This study had several 
limitations. First, it was conducted at an urban tertiary 
cancer center and was designed as a retrospective cohort 
study, potentially limiting the generalizability of our find-
ings. CTCAE is widely accepted as the standard classi-
fication, however, the classification via telephone is not 
standard operating procedure. However, this study is the 
first to report on the use of telephone assessment of AEs 
during ambulatory chemotherapy using CTCAE. More-
over, we found that this assessment is useful for the tri-
age of patients in addition to predicting severe AEs that 
could change clinical schedules. Future research should 
assess that the clinical study of active intervention to pre-
vent severe AEs by use this telephone triage.
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